Navigation Links
Keryx in Medical News

Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference

Corrected Announcement Follows NEW YORK, Oct. 2 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) today announced that I. Craig Henderson, MD, the Company's President, will present an overview of the Company's cancer pipeline at the upcoming William...

Keryx Biopharmaceuticals Settles License Dispute With Alfa Wassermann

... NEW YORK, Aug. 4 /PRNewswire-FirstCall / -- keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) announc...he settlement agreement, Alfa Wassermann is paying keryx US$3,500,000 (of which US$2,750,000 has already been received by keryx and $750,000 is to be paid to...

Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Multiple Myeloma

... NEW YORK, Aug. 3 /PRNewswire-FirstCall/ -- keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) announc...stage of testing, and look forward to working with keryx on this exciting trial." Dr. Paul Richardso...ty. KRX-0401 (perifosine) is in-licensed by keryx from Aeterna Zentaris, Inc. in the United States, ...

Keryx Biopharmaceuticals Inc. Regains Compliance With NASDAQ Listing Requirements

... NEW YORK, June 17 /PRNewswire-FirstCall/ -- keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) announc...s," stated Ron Bentsur, Chief Executive Officer of keryx Biopharmaceuticals. "We believe this represents a... building value for our stockholders." About keryx Biopharmaceuticals, Inc. ...

Keryx Biopharmaceuticals, Inc. Receives Extension for Nasdaq Listing Compliance

... NEW YORK, June 9 /PRNewswire-FirstCall/ -- keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) today a...n stock from The Nasdaq Capital Market. About keryx Biopharmaceuticals, Inc. keryx Biopharmaceuticals is focused on the acquisition, ...

Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results

... keryx to Host Investor Conference Call on Thursday, May ...T NEW YORK, May 13 /PRNewswire-FirstCall/ -- keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ), a biop...or a period of 15 days after the call. ABOUT keryx BIOPHARMACEUTICALS, INC. ...

Keryx Biopharmaceuticals, Inc. Requests an Appeal Hearing After Receiving Notice of Delisting From Nasdaq

... NEW YORK, March 9 /PRNewswire-FirstCall/ -- keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) today a...d value of the Company's common stock. About keryx Biopharmaceuticals, Inc. keryx Biopharmaceuticals is focused on the acquisition, ...

Keryx Biopharmaceuticals Receives Nasdaq Notification

... NEW YORK, Nov. 21 /PRNewswire-FirstCall/ -- keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) today a...no effect at this time on the continued listing of keryx Biopharmaceuticals' common stock on The Nasdaq Capital Market. About keryx Biopharmaceuticals, Inc. ...

Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2008 Financial Results

... keryx to Host Investor Conference Call on Tuesday, Novem... EST NEW YORK, Nov. 10 /PRNewswire-FirstCall/ -- keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ), a bioph..., for a period of 15 days after the call. ABOUT keryx BIOPHARMACEUTICALS, INC. ...

Keryx Biopharmaceuticals' KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology

...30am NEW YORK, Nov. 10 /PRNewswire-FirstCall/ -- keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) today an...e years. KRX-0401 (perifosine) is in-licensed by keryx from Aeterna Zentaris, Inc. (Nasdaq: AEZS ; TSX: ...) in the United States, Canada and Mexico. About keryx Biopharmaceuticals, Inc. ...
Keryx in Medical Technology

AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results for Anti-Cancer Compound Perifosine at ASCO Meeting

Results showed an overall CBR of 52% which compares favorably with the activity of mTOR inhibitors QUEBEC CITY, QC, June 04, 2007 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. , a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that its partner, Keryx B...

Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center

... NEW YORK, July 14 /PRNewswire-FirstCall/ -- keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) announc...eral other important signal transduction pathways. keryx is currently in the process of finalizing late-sta... Ron Bentsur, Chief Executive Officer of keryx Biopharmaceuticals, commented, "We're very excited...

Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer

...er NEW YORK, June 1 /PRNewswire-FirstCall/ -- keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) yesterd...pany. KRX-0401 (perifosine) is in-licensed by keryx from Aeterna Zentaris, Inc. (Nasdaq: AEZS ; TSX:...e same time or used after one another. About keryx Biopharmaceuticals, Inc. ...

Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer

...er NEW YORK, May 31 /PRNewswire-FirstCall/ -- keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) today a...ame time or used after one another. About keryx Biopharmaceuticals, Inc. keryx Biopharmaceuticals is focused on the acquisition, ...

Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401's Activity in the Treatment of Advanced Metastatic Renal Cell Cancer

... NEW YORK, May 29 /PRNewswire-FirstCall/ -- keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) today a...butable to RCC are expected in the US. About keryx Biopharmaceuticals, Inc. keryx Biopharmaceuticals is focused on the acquisition, ...

Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting

...n NEW YORK, Feb. 26 /PRNewswire-FirstCall/ -- keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) today a...trial." Michael S. Weiss, Chairman and CEO of keryx Biopharmaceuticals, remarked, "We believe these da...ment. KRX-0401 (perifosine) is in-licensed by keryx from Aeterna Zentaris, Inc. (Nasdaq: AEZS ; TSX:...

Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology

... NEW YORK, Dec. 9 /PRNewswire-FirstCall/ -- keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) today a... S. Weiss, Chairman and Chief Executive Officer of keryx Biopharmaceuticals, commented, "We are grateful fo.... KRX-0401 (perifosine) is in-licensed by keryx from Aeterna Zentaris, Inc. (Nasdaq: AEZS ; TSX:...

Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology

...nemia NEW YORK, June 3 /PRNewswire-FirstCall/ -- keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) today an...city profile seen to date. Michael Weiss, CEO of keryx Biopharmaceuticals, commented "We are encouraged b...e years. KRX-0401 (perifosine) is in-licensed by keryx from Aeterna Zentaris, Inc. (Nasdaq: AEZS ; TSX: ...

Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois

...E450a NEW YORK, June 2 /PRNewswire-FirstCall/ -- keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) today an...e years. KRX-0401 (perifosine) is in-licensed by keryx from Aeterna Zentaris, Inc. (Nasdaq: AEZS ; TSX: ...) in the United States, Canada and Mexico. About keryx Biopharmaceuticals, Inc. ...

Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial

... NEW YORK, March 27 /PRNewswire-FirstCall/ -- keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) announce...SMC for a safety problem or safety signal. About keryx Biopharmaceuticals, Inc. keryx Biopharmaceuticals is focused on the acquisition, ...
Keryx in Biological Technology

Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results

... NEW YORK, Aug. 5 /PRNewswire-FirstCall/ -- keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ), a biop...Phase 3 program for Zerenex shortly, at which time keryx will be in the compelling position of having two P...ded, "I am excited by the opportunity to transform keryx into a late-stage development company and maximize...

Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT

... NEW YORK, Aug. 4 /PRNewswire-FirstCall/ -- keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) will ho...utive Officer of the Company, will host the call. keryx will announce its financial results for this perio...//www.keryx.com , prior to the call. About keryx Biopharmaceuticals, Inc. ...

AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma

...s Inc. (NASDAQ: AEZS , TSX: AEZ), ("the Company") a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ), its partner and licensee for perifosine in the North American market, has reached an agreement with the U....

Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients

... NEW YORK, June 8 /PRNewswire-FirstCall/ -- keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) today a...adequate to support entry into a Phase 3 program. keryx is in the process of finalizing the Phase 3 progra... per annum over the last five years. About keryx Biopharmaceuticals, Inc. ...

Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer

... NEW YORK, May 20 /PRNewswire-FirstCall/ -- keryx Biopharmaceuticals, Inc. (the "Company") (Nasdaq: ... am extremely excited for this opportunity to lead keryx at this key juncture for the Company. We have two...r change in control of the Company. About keryx Biopharmaceuticals, Inc. ...

AEterna Zentaris to Present Data Supporting Evaluation of AEZS-108 in Prostate Cancer at Upcoming ASCO Meeting

... Partner keryx to present Phase 2 data on perifosine for multiple...sine Additionally, AEterna Zentaris' partner, keryx Biopharmaceuticals, announced yesterday that it wi...tor compound, perifosine, during the ASCO meeting. keryx is currently developing perifosine in multiple Pha...

Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology

...) NEW YORK, May 18 /PRNewswire-FirstCall/ -- keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) today a...CO website: http://www.asco.org/ . About keryx Biopharmaceuticals, Inc. keryx Biopharmaceuticals is focused on the acquisition, ...

Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2009 Financial Results on Thursday, May 14, 2009 at 8:30am EDT

... NEW YORK, May 11 /PRNewswire-FirstCall/ -- keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) will ho...utive Officer of the Company, will host the call. keryx will announce its financial results for this perio...p://www.keryx.com , prior to the call. About keryx Biopharmaceuticals, Inc. ...

Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer

... NEW YORK, April 23 /PRNewswire-FirstCall/ -- keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) today a... and Olivetti Corporation of America. ABOUT keryx BIOPHARMACEUTICALS, INC. keryx Biopharmaceuticals is focused on the acquisition, ...

Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research

... NEW YORK, April 21 /PRNewswire-FirstCall/ -- keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) today a... be obtained by contacting the Company. About keryx Biopharmaceuticals, Inc. keryx Biopharmaceuticals is focused on the acquisition, ...
Other Tags
(Date:10/20/2014)... York, NY (PRWEB) October 20, 2014 ... based non-profit organization that helps New Yorkers living ... positive changes toward health, housing, recovery and self-sufficiency. ... have transformed the local community through their tireless ... Director, Marc Shapses , has been selected ...
(Date:10/20/2014)... 2014 hc1.com today announced the ... solution that enables healthcare organizations of all sizes ... customer relationship management (“CRM”) solution. , Designed from ... of the healthcare industry, the hc1 Healthcare Relationship ... patients by combining healthcare CRM, HIPAA-compliant collaboration, and ...
(Date:10/20/2014)... Kennewick, WA (PRWEB) October 20, 2014 ... new workflow management software application. The new module ... ensure patients receive full life-cycle quality care. , This ... to others within their practice, attach a to-do item ... see fit, and even set up reoccurring reminders for ...
(Date:10/20/2014)... 20, 2014 Myoderm ... Assistant Director of their CentralSource service. ... the innovative turnkey drug sourcing, distribution, and management ... over 12 years of industry experience, in both ... the peak of their international success to help ...
(Date:10/20/2014)... October 20, 2014 Based on ... the only imaging assays capable of determining DNA ... test.  With these three dimensions of high-resolution data, ... detect the widest range of disease-causing genetic rearrangements, ... by other genomic tools, including today’s advanced sequencing ...
Breaking Medicine News(10 mins):Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:My Clients Plus Announces New Workflow Management Software 2Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3
(Date:10/16/2014)... Institute of Marine Science have received a 3-year, ... identify the streams and wetlands most vulnerable to ... local governments and citizens conserve these important ecosystems. ... of tidal-marsh observations first gathered by VIMS scientists ... can today,s researchers accurately map the slow but ...
(Date:10/16/2014)... Calif. (October 16, 2014) – Post-menopausal women experienced ... on hormone levels or genital bleeding, after 12 ... an investigational fermented soy germ-based nutritional supplement previously ... to a new peer-reviewed pilot study reported in ... (NAMS) annual scientific meeting. , "These data ...
(Date:10/15/2014)... University Mainz (JGU) as a full member, ensuring ... a significant nationwide standing in the field of ... Gutenberg University Mainz as a full member of ... and international competition for the best minds and ... proud that Mainz University has been recognized as ...
Breaking Biology News(10 mins):EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3
Other Contents